Cullinan Historical Income Statement
CGEM Stock | USD 23.46 0.52 2.17% |
Historical analysis of Cullinan Oncology income statement accounts such as Selling General Administrative of 44.6 M, Total Revenue of 0.0 or Cost Of Revenue of 325.5 K can show how well Cullinan Oncology LLC performed in making a profits. Evaluating Cullinan Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cullinan Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cullinan Oncology LLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cullinan Oncology LLC is a good buy for the upcoming year.
Cullinan |
About Cullinan Income Statement Analysis
Cullinan Oncology LLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cullinan Oncology shareholders. The income statement also shows Cullinan investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cullinan Oncology Income Statement Chart
Cullinan Oncology LLC Income Statement is one of the three primary financial statements used for reporting Cullinan's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cullinan Oncology LLC revenue and expense. Cullinan Oncology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Cullinan Oncology's Research Development is very stable compared to the past year. As of the 21st of May 2024, Net Interest Income is likely to grow to about 22.7 M, though Operating Income is likely to grow to (181.1 M). Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts Cullinan Oncology LLC generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Cullinan Oncology LLC minus its cost of goods sold. It is profit before Cullinan Oncology operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Operating Income
Operating Income is the amount of profit realized from Cullinan Oncology LLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cullinan Oncology LLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Cullinan Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. At this time, Cullinan Oncology's Research Development is very stable compared to the past year. As of the 21st of May 2024, Net Interest Income is likely to grow to about 22.7 M, though Operating Income is likely to grow to (181.1 M).
2023 | 2024 (projected) | Non Recurring | 183.9K | 97.2K | Research Development | 148.2M | 155.6M |
Cullinan Oncology income statement Correlations
Click cells to compare fundamentals
Cullinan Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cullinan Oncology income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Selling General Administrative | 5.5M | 17.1M | 29.1M | 40.2M | 42.5M | 44.6M | |
Operating Income | (22.3M) | (60.3M) | (68.0M) | 144.6M | (190.6M) | (181.1M) | |
Net Income From Continuing Ops | (21.7M) | (59.5M) | (65.6M) | 109.2M | (155.1M) | (147.3M) | |
Ebit | (22.3M) | (60.3M) | (68.0M) | 144.6M | (190.6M) | (181.1M) | |
Total Operating Expenses | 22.3M | 60.3M | 86.9M | 132.1M | 190.3M | 199.9M | |
Income Before Tax | (21.7M) | (59.5M) | (67.5M) | 151.3M | (169.2M) | (160.8M) | |
Total Other Income Expense Net | 616K | 877K | 469K | 6.7M | 21.4M | 22.5M | |
Net Income Applicable To Common Shares | (20.7M) | (51.8M) | (65.6M) | 111.2M | 127.9M | 134.3M | |
Net Income | (20.0M) | (50.8M) | (65.0M) | 111.2M | (153.2M) | (145.5M) | |
Income Tax Expense | (1.6M) | (8.6M) | (2.4M) | 42.1M | (14.1M) | (13.4M) | |
Research Development | 16.8M | 43.2M | 57.8M | 91.9M | 148.2M | 155.6M | |
Net Interest Income | 620K | 888K | 477K | 6.6M | 21.6M | 22.7M | |
Interest Income | 620K | 888K | 477K | 6.6M | 21.6M | 22.7M | |
Depreciation And Amortization | 70K | 62K | 53K | (553.6M) | 310K | 325.5K | |
Other Operating Expenses | 22.3M | 60.3M | 86.9M | 132.1M | 190.6M | 200.2M | |
Ebitda | (22.2M) | (60.3M) | (67.9M) | (408.9M) | (190.3M) | (199.9M) | |
Reconciled Depreciation | 70K | 62K | 53K | 93K | 310K | 325.5K | |
Minority Interest | 864K | 1.3M | (1.9M) | (2.0M) | 1.9M | 2.0M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Cullinan Oncology LLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Cullinan Oncology LLC information on this page should be used as a complementary analysis to other Cullinan Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Cullinan Stock analysis
When running Cullinan Oncology's price analysis, check to measure Cullinan Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cullinan Oncology is operating at the current time. Most of Cullinan Oncology's value examination focuses on studying past and present price action to predict the probability of Cullinan Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cullinan Oncology's price. Additionally, you may evaluate how the addition of Cullinan Oncology to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Cullinan Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.22) | Return On Equity (0.29) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.